InvestorsHub Logo
Followers 12
Posts 1019
Boards Moderated 0
Alias Born 03/24/2013

Re: jbog post# 17821

Monday, 10/16/2017 5:03:22 AM

Monday, October 16, 2017 5:03:22 AM

Post# of 20689
jbog... The recent Teva PR says:

In additional litigation, Teva brought suit against five Abbreviated New Drug Application (ANDA) filers, including Mylan, for infringement of a patent covering a manufacturing process for glatiramer acetate product.



Dew is suggesting that as far as API is manufactured outside of US (e.g. Natco manufactures in India), MYL doesn't need to worry about process patents of TEVA or MNTA. I wonder: Why would TEVA waste their resources if the matter is not worthy of litigation or where the chances of winning are zero?